BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute for Bioengineering of Catalonia - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute for Bioengineering of Catalonia
X-ORIGINAL-URL:https://ibecbarcelona.eu
X-WR-CALDESC:Events for Institute for Bioengineering of Catalonia
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20210310T120000
DTEND;TZID=Europe/Madrid:20210310T140000
DTSTAMP:20260426T133307
CREATED:20210218T161413Z
LAST-MODIFIED:20210301T092607Z
UID:81895-1615377600-1615384800@ibecbarcelona.eu
SUMMARY:Online IBEC Seminar: Ester Caffarel
DESCRIPTION:Breaking Paradigms: Delivering insulin orally\nEster Caffarel\, MIT \nBiologics have revolutionized disease treatment; however\, their rapid degradation and poor absorption in the gastrointestinal (GI) tract generally limit their administration to parenteral routes. Devices for the oral delivery of biologics must aid in both localization and permeation to achieve systemic drug uptake. For this purpose\, we have developed various ingestible devices that rapidly propel drug-loaded posts into the tissue wall of the different organs of the GI tract.
URL:https://ibecbarcelona.eu/event/online-ibec-seminar-ester-caffarel/
CATEGORIES:IBEC Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20210312T100000
DTEND;TZID=Europe/Madrid:20210312T120000
DTSTAMP:20260426T133307
CREATED:20210203T123720Z
LAST-MODIFIED:20210303T105835Z
UID:81355-1615543200-1615550400@ibecbarcelona.eu
SUMMARY:Online IBEC Seminar: Paolo Arosio
DESCRIPTION:Membraneless compartments based on intrinsically disordered proteins: from biology towards new protein materials\nPaolo Arosio\, Institute for Chemical and Bioengineering\, ETH Zurich \nIn the last few years\, discoveries in biology are revealing that a class of intrinsically disordered protein sequences plays an important role in the formation of cellular membraneless compartments by spontaneous liquid-liquid phase separation of proteins and nucleic acids. These compartments underlie several important functions and can act as microreactors\, in which environment and composition are carefully regulated in space and time. These observations inspired us to exploit these biological sequences to mimic these membraneless compartments on the bench\, towards the development of high-performance open microreactors\, with applications for instance in biocatalysis. With these sequences we can regulate not only the dynamic process of phase separation but also several properties of the resulting compartments\, including uptake of client molecules\, polarity and material properties. With this control we can\, in turn\, regulate biochemical reactions occurring within the compartments. \nWe further show the development of droplet microfluidic platforms to characterize multiple properties of the open compartments\, including both thermodynamics and dynamics of phase separation. We illustrate these concepts by investigating an established in vitro model of Processing bodies consisting of the phase separation of the DEAD-box protein ATPase Dhh1 in the presence of ATP and RNA. \nThis seminar will take place online \nKnow more about Paolo Arosio’s research here
URL:https://ibecbarcelona.eu/event/online-ibec-seminar-paolo-arosio/
CATEGORIES:IBEC Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20210319T100000
DTEND;TZID=Europe/Madrid:20210319T120000
DTSTAMP:20260426T133307
CREATED:20210203T121424Z
LAST-MODIFIED:20210315T124852Z
UID:81339-1616148000-1616155200@ibecbarcelona.eu
SUMMARY:Clinical Colloquia: Anna Novials
DESCRIPTION:Diabetes\, where are we?\nAnna Novials\, PI of the group “Pathogenesis and Prevention of Diabetes” at IDIBAPS/Clinic Hospital of Barcelona and member of CIBERDEM network. \nDiabetes mellitus (DM) is a group of chronic metabolic disorders all characterized by hyperglycemia. It occurs either when the pancreas does not produce enough insulin or when the peripheral tissues cannot effectively use the insulin it produces. The global prevalence of diabetes and impaired glucose tolerance (the intermediate transition between normal blood glucose levels and diabetes) has been increasing over recent decades. The International Diabetes Federation (IDF) reported that in 2019 there were 463 million people between 20-79 years worldwide with diabetes\, accounting for the 9.3 % of the global adult population. If this trend continues\, it is expected to increase to 700 million by 2045. Furthermore persistent high blood glucose levels cause generalized vascular damage affecting the kidneys (nephropathy)\, the eyes (retinopathy)\, the nerves (neuropathy) and the heart (cardiovascular disease)\, leading to disabilities and premature death. The World Health Organization (WHO) reported diabetes to be the seventh leading cause of death. As a consequence the economic burden of diabetes has a high impact on the global health-care system. \nThe first national study in Spain published in 2012 (the Di@bet.es Study) revealed that the overall prevalence of DM in individuals ≥18 years old in our country was 13.8% and\, about a half of them (6%) had unknown diabetes. In addition to this alarming values\, the prevalence rates of isolated impaired fasting glucose (IFG)  and isolated impaired glucose tolerance (IGT)  3.4% and 9.2%\, respectively (2). Taken together\, this study uncovered that almost 30% of the study population had some carbohydrate disturbance. \nType 2 Diabetes (T2D) accounts for the vast majority (around 90%) of diabetes worldwide. It can be effectively managed through education\, adoption of healthy lifestyles\, combined with medication as required. The pathogeny of T2D is extremely complex and comprises all the organs that work coordinately to maintain energy and glucose homeostasis.  It is established that when the cross-talk between organs (pancreas\, liver\, muscle\, adipose tissue\, brain \,etc )is altered\, then the main pathogenic events which are insulin secretory defects and insulin resistance appear as a hallmark of T2D. All current treatment for T2D are adressed to  target molecular pathways in different tissues. \nType 1 diabetes (T1D) is the major cause of diabetes in childhood. Patients need an uninterrupted supply of insulin for life. The pathogeny of diabetes consists in alteration in the autoinmunity. The main cause is not yet been stablished. The advances in the treatment remain  dissapointing . Although technology applied to diabetes is in continuos progress\, patients are still using the same treatment as 100 years ago\, when insulin was discovered. \nCollectively\, these results  evidence the need for more clinical and preventive intervention programs and highlight the importance of carrying out more basic research in order to understand the underlying mechanisms of the disease. \n\nDr. Anna Novials is endocrinologist at Hospital Clinic de Barcelona and  leader group of research at IDIBAPS. She received her PhD from the University of Barcelona\, in 1989\, focusing her studies on the chronic effect of glucotoxicity on pancreatic function in patients with type 2 diabetes. A postdoctoral stay at the University of Cambridge and collaborations with the University of Oxford enriched her scientific and technical knowledge of molecular biology\, turning her research objectives toward the molecular mechanisms that affect pancreatic islet function in diabetes\, which she would then develop at the Hospital Clinic de Barcelona\, going on to lead her own research group. \nFrom 1998 to 2008\, Dr. Novials conducted her clinical activity at the Sardà Farriol Foundation in Barcelona\, first as Head of the Diabetology Unit and later as Executive Director. Here she devoted her efforts to promoting educational tools to help patients adhere to exercise programs as part of their diabetes treatment plan. In 2008\, she rejoined the IDIBAPS as leader of a clinical and basic research team. Since 2010\, she has also served as an Executive Committee member of the Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM). Finally\, Dr. Novials is the former  President of the Spanish Diabetes Society and as served as member of the EASD-EU Committee of the European Association for the Study of Diabetes to advocate for diabetes research. \nThis clinical colloquia will take place online at the GoToMeeting platform
URL:https://ibecbarcelona.eu/event/clinical-colloquia-anna-novials/
CATEGORIES:IBEC Seminar
END:VEVENT
END:VCALENDAR